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Abstract—Acute  mountain  sickness  (AMS)  is  a  symptom 
complex noticed commonly among high altitude travelers. The 
occurrence of AMS depends on multiple factors that have been 
studied extensively. However, AMS in individuals with neuro-
logical impairments has not been considered in detail. A total 
of 168  subjects,  including  active  controls,  inactive  controls, 
and those with spinal cord injury (SCI), multiple sclerosis, and 
traumatic brain injury (TBI), were studied at the National Vet-
erans Winter Sports Clinic in Snowmass, Colorado, from 2007 
to 2009 for the occurrence of AMS. Lake Louise Score was 
used to quantify symptoms. A higher than anticipated occur-
rence  of  AMS  (42.85%)  among  the  study  population  was 
noted, with significantly higher Lake Louis Scores among ath-
letes  with  neurological  impairments.  Disability  group,  prior 
history of AMS, and prior occurrence of headache at high alti-
tude could be used as predictors for the development of AMS 
symptoms. More research is warranted specifically targeting 
the interaction between factors affecting AMS and the patho-
physiology of neurological impairments like SCI and TBI to 
further our understanding about prophylactic medications and 
treatments for AMS, especially because many military person-
nel with neurological impairments continue on Active Duty.
Key words: acute mountain sickness, altitude sickness, AMS, 
disability, Lake Louis Score, multiple sclerosis, neurological 
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INTRODUCTION AND BACKGROUND
Acute mountain sickness (AMS) is a symptom com-
plex characterized by headache and at least one of the 
following: nausea/vomiting, fatigue, dizziness, and diffi-
culty sleeping; it appears 6–12 h after arrival at high alti-
tude (HA) and usually resolves within 1–3 d [1]. The 
occurrence of AMS or HA illness (HAI) depends on mul-
tiple  factors  like  study  population  [1–3],  geographic 
region  [4–6],  individual  susceptibility  [1,6–7],  rate  of 
ascent to altitude [1,3], absolute height achieved [1,4], 
and height at which the individual resides/lives before 
beginning the climb [1,8–9].
Although the multiple factors just mentioned have been 
evaluated individually in various studies, the occurrence of 
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AMS in individuals with neurological impairments has not 
been  an  important  topic  of  focus.  Because  an  increased 
number  of  military  personnel  with  neurological  impair-
ments like traumatic brain injury (TBI), spinal cord injury 
(SCI), and polytrauma are returning to Active Duty and 
being deployed to HA environments, flying in nonpressur-
ized aircraft, and participating in HA sporting events as part 
of rehabilitation, an in-depth analysis to study the occur-
rence  of  AMS  in  this  population  was  done  at  the  2007 
National  Veterans  Winter  Sports  Clinic  (NVWSC)  in 
Snowmass, Colorado (elevation of 2,470–3,813 m). Dici-
anno et al. published the findings from this pilot study in 
2008 [10]. While no differences were found among control 
subjects  and  subjects  with  various  neurological  impair-
ments with respect to occurrence of AMS, more subjects 
were needed to make a definitive conclusion. The study 
did, however, show that AMS in individuals with disabili-
ties due to neurological impairments was at least as com-
mon and as severe as in those without disabilities, with the 
most common symptoms being fatigue and weakness, sim-
ilar to what has been reported in other studies [4].
While the pathogenesis of AMS is still unclear, mul-
tiple studies have explained the series of adjustments the 
body goes through to meet the hypoxemic challenge at 
HA.  This  process,  defined  as  acclimatization,  has  two 
distinct systems:
1. Increase in altitude causes the barometric pressure to 
fall, thereby decreasing the reduction of partial pres-
sure of oxygen, causing hyperventilation and respira-
tory alkalosis. The body compensates for this alkalosis 
by excreting bicarbonates in the urine within 24–48 h 
of exposure to HA [11–12].
2. In  addition,  cerebral  vasodilatation  accompanied  by 
alterations in the blood-brain barrier secondary to the 
altitude-induced hypoxemia and an increase in vascu-
lar hydrostatic pressure also occur among HA travelers 
[13]. These combined effects lead to cerebral edema. 
The ability to compensate for this edema greatly varies 
with  every  individual  [1,11–12],  depending  on  the 
ability of his or her spinal cord to expand and accom-
modate for the additional fluid [14].
In individuals with neurological impairments, multi-
ple changes within the central nervous system following 
injury  may  potentially  affect  these  processes.  For 
instance, individuals with SCI have central canal expan-
sion and loss of uniform cellular arrangement and thick-
ening of the wall of the canal [15–16] and those with TBI 
and multiple sclerosis (MS) have alterations in the blood-
brain barrier [17–18]. In addition, the cardiovascular and 
metabolic  alterations  secondary  to  these  neurological 
impairments  (SCI,  TBI,  and  MS)  involving  the  auto-
nomic nervous system [17–19] could hinder the compen-
satory mechanisms, causing an increase in the severity of 
the  symptoms,  particularly  in  those  with  tetraplegia 
because they may experience autonomic dysreflexia.
With this background, the study was extended to the 
2008 and 2009 NVWSC at Snowmass, Colorado, with 
the following specific aims:
1. To compare the occurrence of AMS in a population of 
athletes with neurological impairments to physically 
active and physically inactive control subjects at HA. 
We hypothesized that the occurrence and severity of 
AMS  in  individuals  with  neurological  impairments 
would be higher than in the control groups.
2. To compare the occurrence of AMS in athletes based 
on their disabilities. We hypothesized that among indi-
viduals  with  neurological  impairments,  individuals 
with tetraplegia from SCI would have a higher occur-
rence than the other disability groups.
Further, no clinical feature or test has been shown to 
predict an individual’s susceptibility to developing AMS 
at HA with any reliability [3]. Based on previous studies 
[2–3] and our experience with studying AMS in the past, 
we  conducted  an  analysis  to  evaluate  the  factors  that 
could have a clinically significant predictive capacity for 
high Lake Louise Score (LLS).
METHODS AND STATISTICS
Similar to the previous study in 2007 [10], we recruited 
registered athletes, trainers, and volunteers from the regis-
tration exposition, medical staff meeting, and dining facili-
ties at the 2008 and 2009 NVWSC. A similar protocol used 
to obtain the preliminary data in 2007 [10] was followed. 
Inclusion criteria were being between the age of 18 and 
80 and belonging to one of the following categories: (1) 
physically  active  controls:  those  trainers,  volunteers,  or 
individuals with visual impairments who were participating 
in sports activities and had no other disabilities; (2) physi-
cally inactive controls: those trainers, volunteers or individ-
uals  with  visual  impairments  who  were  not  physically 
participating in sports activities and had no disabilities; and 
(3) athletes with disabilities: those registered athletes who 
defined themselves as having a physical disability or who 
used assistive technology for mobility or self-care. There 255
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were no exclusion criteria. However, before participating in 
the NVWSC, applicants are screened by a medical team for 
any medical condition that would present a danger to the 
participant. Examples of these conditions include unstable 
angina,  severe  cardiomyopathy,  renal  failure  requiring 
hemodialysis,  severe  pulmonary  fibrosis,  and  new-onset 
seizure disorder.
Subjects who met the eligibility criteria were asked 
to complete a medical and demographics survey as well 
as  the  questionnaire  to  measure  the  LLS  (Appendix, 
available online only) [20] on day 1 of enrollment, fol-
lowed by one LLS questionnaire on each of the next 2 
consecutive days. In addition, we performed a retrospec-
tive chart review of the medical charts of all individuals 
who presented at the clinic, recording the number of gen-
eral visits, the number of visits that resulted in a diagno-
sis of AMS, and the disability type. We also collected the 
number of alcoholic drinks the subjects consumed each 
day because this had not been collected in the prior study.
Diagnostic Criteria
AMS was defined as scoring at least 3 on the LLS, 
plus the presence of a headache and at least one of the 
following symptoms: change in appetite, nausea/vomit-
ing, fatigue, weakness, dizziness or light-headedness, or 
difficulty sleeping [1,4,10]. Subjects were encouraged to 
report only symptoms that were new or different from 
baseline. Subjects who were diagnosed with AMS based 
on this questionnaire were referred to the medical area 
for further medical evaluation. The severity of the AMS 
was described as mild, moderate, and severe if the LLS 
scores were 3, 4–5, and 6 or more, respectively, after the 
basic AMS criteria were met [10].
Statistical Analysis
The overall occurrence of AMS in the entire study 
population and in each group was calculated based on the 
number of subjects who met the diagnostic criteria for 
AMS on at least one LLS on any of the 3 d. We also tal-
lied the number of people receiving a diagnosis of AMS 
in  the  medical  area  for  comparison.  The  base  altitude 
from which subjects traveled was determined by using a 
database of U.S. Census Bureau information that links 
zip codes to altitudes (http://www.zipdatafiles.com, TPS 
Products and Services, Inc; New Castle, California). All 
alpha levels were set to 0.05 a priori. IBM SPSS Statis-
tics 19 (IBM Corp; Armonk, New York) was used for all 
statistical analyses.
Baseline Analysis
The  participants  were  divided  into  three  groups: 
(1) active control, (2) inactive control, and (3) athletes 
with disabilities. Chi-square or Fischer exact tests were 
used to calculate the differences between the groups in 
terms of baseline demographic or medical variables that 
were ordinal or nominal. Kruskal-Wallis or analysis of 
variance tests were used to compare groups with respect 
to other baseline variables that were continuous, such as 
age, average number of times in the last year the subject 
traveled to HA, and average home altitude.
Level I Analysis
An analysis of covariance (ANCOVA) test was used 
to  analyze  the  differences  across  the  subgroups  with 
respect to the average LLS, the occurrence or number of 
cases  diagnosed,  duration  of  symptoms,  number  of 
severe cases, and median number of days between arrival 
at the clinic and the time when the participant completed 
the first LLS. We factored in any baseline variables that 
were significantly different across the subgroups. A post 
hoc analysis was performed to determine where differ-
ences in subgroups occurred.
Level II Analysis
The  participants  were  divided  into  six  groups: 
(1) active control, (2) inactive control, (3) TBI, (4) paraple-
gia, (5) tetraplegia, and (6) MS. The same parameters as in 
the level I analysis were used to evaluate for differences in 
baseline values and in main outcome variables, again using 
ANCOVA statistics with similar post hoc analyses.
Level III Analysis
To predict an individual’s susceptibility for develop-
ing AMS, we performed a regression analysis to evaluate 
possible factors that could have a significant clinical pre-
dictive capacity for high LLS. Age, sex, type of disability, 
prior history of HAI, and occurrence of headache in HA in 
the past were considered as the predictor variables. Kend-
all  tau-b  was  used  to  identify  possible  correlations 
between these factors and LLS averaged over 3 d. Based 
on this correlation analysis, a backward regression analy-
sis was performed to build a model to predict the average 
LLS for travelers with neurological impairments to HA.
Alcohol Analysis
A Pearson correlation analysis between the number 
of drinks consumed by each individual in a particular day 256
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and the LLS for the same day was performed to study 
whether there was any relationship between alcohol con-
sumption and LLS.
RESULTS
Subjects
Overall,  there  were  1,130  participants  in  the  2007, 
2008, and 2009 NVWSC, of which 125 (11.06%) were 
females. A total of 178 subjects expressed interest in this 
study. Two subjects did not complete the informed con-
sent  document,  but  the  remaining  176  individuals  who 
had  agreed  to  participate  in  the  study  completed  the 
informed consent document. However, 8 subjects had par-
ticipated in the study for more than 1 yr, and hence, only 
the  data  from  their  first  year  of  participation  were 
included.  Of  these  168  subjects,  54  (32.14%)  were 
females and 114 (67.86%) males. A total of 135 (80.35%) 
of the 168 subjects were U.S. veterans. Racial/ethnic dis-
tribution was 112 (66.7%) Caucasian, 27 (16.1%) African 
American/Black, 12 (7.1%) Hispanic, 5 (3%) American 
Indian, 3 (1.8%) Asian American, and 9 (5.4%) more than 
one ethnicity. Table 1 shows the disability types of all the 
participants in the NVWSC each year. Twenty-one ampu-
tees participated in the study, eight of whom had a second-
ary diagnosis of TBI and, hence, were grouped along with 
the  TBI  subgroup.  The  remaining  13  amputees  were 
grouped with the active controls.
Analysis
After the exclusion of the repeat data, data from 168 
subjects  were  analyzed.  The  subgroups  differed  with 
respect to age and sex in both levels of analysis (Tables 2 
and 3). Autonomic
Disability
No. of Athletes
2007 2008 2009 Total
Traumatic Brain Injury 50 64 73 187
Spinal Cord Injury 144 144 135 423
Stroke 5 15 12 32
Visual Impairment 58 54 75 187
Amputation 69 63 53 185
Multiple Sclerosis 36 40 25 101
Other 12 29 27 68
 dysreflexia was also present in some 
of the participants with tetraplegia. All subjects traveled 
to the NVWSC in less than 1 d, and most began partici-
pating in sporting events 24 h after arrival.
A total of 72 (42.85%) subjects met the diagnostic 
criteria for AMS, with 22 (13.09%) being diagnosed with 
severe illness. There were significant differences in the 
average  LLS  (mean  ±  standard  deviation)  among  the 
active controls (1.2 ± 1.1), inactive controls (1.7 ± 1.7), 
and athletes with disabilities (2.4 ± 1.9) in the level I 
analysis  (p  =  0.01)  ( Table  4).  The  post  hoc  analysis 
showed that the average LLS was significantly higher in 
athletes with neurological impairments than in the active 
controls (p = 0.01) and inactive controls (p = 0.04). There 
was a trend for the paraplegia group to have the highest 
LLSs, but there were no statistically significant differ-
ences in the average LLSs among the subgroups in the 
level II analysis. Also, there were no significant differ-
ences in the total AMS scores, number of cases diag-
nosed, the duration of symptoms, number of severe cases, 
or median days from arrival to completion of the first 
LLS among subject groups in level I or level II analyses 
(Table  5). Overall, fatigue and headache were the most 
commonly reported symptoms (Table 6).
Of the 1,130 participants at the NVWSC, there were 
548 visits to the medical treatment area (Table 7). There 
were 348 unique athletes who visited the medical treat-
ment area, and 22 (6.32%) were diagnosed with AMS. 
Diagnoses of those receiving treatment were SCI (eight), 
TBI (four), visual impairment (two), amputations (two), 
and other (three). Patients received treatment with oxy-
gen,  hydration,  nonsteroidal  anti-inflammatory  drugs, 
acetaminophen,  acetazolamide,  and  dexamethasone, 
depending on their severity of symptoms. No one had to 
return to low altitude because of the symptoms.
Three  variables,  the  presence  of  a  neurological 
impairment, prior history of AMS, and prior history of 
occurrence of headache at HA, had significant positive 
correlations with average LLS and were considered for 
the regression analysis (Table 8). The significant F val-
ues for both the models indicated a high overall fit of the 
model for this data. The models also met all the assump-
tions of a multiple regression, indicating this model could 
be generalized to a larger population (Table 9).
No significant correlation was found in the correla-
tion analysis performed to study the relationship between 
alcohol consumption and LLS.                
Table 1.
Medical conditions of all 2007–2009 National Veterans Winter Sports 
Clinic participants.
Note: Several participants carried >1 diagnosis.Variable
Active Controls
(n = 19)
Inactive Controls
(n = 39)
Athletes with Disabilities
(n = 110)
p -Value
Age, Mean ± SD (yr) 53.42 ± 12.94 50.64 ± 11.84 45.93 ± 11.8 0.03*
Female, n (%) 14 (25.9) 17 (31.5) 23 (42.6) <0.001*
Past Medical History, n (%)
4 (21.1) 12 (30.8) 30 (27.3) 0.74
6 (31.6) 10 (25.6) 36 (32.7) 0.71
1 (5.3) 0 8 (7.2) 0.22
NA NA 3 (7.9) 0.001*
1 (5.3) 1 (2.6) 7 (6.3) 0.66
6 (31.6) 5 (12.8) 18 (16.4) 0.19
Sought Treatment for HA, n (%) 4 (2.1) 3 (7.7) 17 (15.4) 0.33
Taking Prophylactic Medication, n (%) 0 2 (5.1) 6 (5.4) 0.48
Headaches at HA, n (%) 10 (52.6) 15 (38.5) 37 (33.6) 0.28
Traveled to HA in Last 2 mo, n (%) 6 (31.6) 13 (33.3) 45 (40.1) 0.58
Times in Last Year Traveled to HA, Mean ± SD 0.7 ± 1.1 0.9 ± 1.8 0.5 ± 0.8 0.25
Home Altitude (m), Mean ± SD 538.7 ± 664.0 371.4 ± 539.8 363.5 ± 623.9 0.11
Variable
Active Controls
(n = 19)
Inactive Controls
(n = 39)
TBI
(n = 29)
Paraplegia
(n = 38)
Tetraplegia
(n = 28)
MS
(n = 15)
p-Value
Age (yr), Mean ± SD 53.42 ± 12.94 50.64 ± 11.84 41.67 ± 13.87 47.39 ± 11.28 46.64 ± 11.51 48.53 ± 6.72 0.03*
Females, n (%) 14 (73.7) 17 (43.6) 4 (13.8) 7 (18.4) 4 (14.3) 8 (53.3) <0.001*
Past Medical History, n (%)
4 (21.1) 12 (30.8) 8 (27.6) 9 (23.7) 12 (42.9) 1 (6.7) 0.19
6 (31.6) 10 (25.6) 10 (34.5) 14 (36.8) 9 (32.1) 3 (30.0) 0.84
1 (5.3) 0 3 (10.3) 3 (7.9) 2 (7.1) 0 0.32
NA NA NA 3 (7.9) NA NA 0.001*
1 (5.3) 1 (2.6) 4 (13.8) 2 (5.3) 1 (3.6) 0 0.47
6 (31.6) 5 (12.8) 3 (10.3) 10 (26.3) 4 (14.3) 1 (6.7) 0.21
Sought Treatment for HA, n (%) 4 (2.1) 3 (7.7) 5 (17.2) 8 (21.1) 4 (14.3) 0 0.25
Taking Prophylactic Medication, n (%) 0 2 (5.1) 4 (13.8) 2 (5.3) 2 (7.1) 0 0.50
Headaches at HA, n (%) 10 (52.6) 15 (38.5) 8 (27.6) 15 (39.5) 9 (32.1) 5 (33.3) 0.61
Traveled to HA in Last 2 mo, n (%) 6 (31.6) 13 (33.3) 13 (44.8) 16 (42.1) 11 (39.3) 5 (33.3) 0.89
Times in Last Year Traveled to HA, 
Mean ± SD
0.7 ± 1.1 0.9 ± 1.8 0.4 ± 0.7 0.6 ± 1.1 0.5 ± 1.1 0.5 ± 0.7 0.61
Home altitude (m), Mean ± SD 538.7 ± 664.0 371.4 ± 539.8 281.3 ± 532.6 166.8 ± 263.1 262.9 ± 481.3 744.2 ± 951.7 0.15
Variable
Active Controls
(n = 19)
Inactive Controls
(n = 39)
Athletes with Disabilities
(n = 110)
p-Value
Average LLS, Mean ± SD 1.2 ± 1.1 1.7 ± 1.7 2.4 ± 1.9 0.01*
Cases Diagnosed, No. (%) 8 (42.1) 14 (35.9) 50 (45.4) 0.58
Duration of AMS Symptoms, No. of d (Range) 1 (1–2) 1 (1–3) 1 (1–3) 0.48
Severity, No. (%) 1 (5.3) 3 (7.7) 24 (21.8) 0.14
Days Subjects at Clinic when Completed First LLS, 
Median (Range)
1 (0–3) 2 (0–4) 2 (0–4) 0.08
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Table 2.
Subject group demographics, based on athletes with disabilities as one subgroup.
   Hypertension
   Hypercholesterolemia
   Heart Disease
   Autonomic Dysreflexia
   Peripheral Vascular Disease
   Any HAI
*Statistically significant difference.
HA = high altitude, HAI = high altitude illness, NA = not applicable, SD = standard deviation.
Table 3.
Subject group demographics, based on athletes with disabilities and subgroups based on their neurological impairment.
   Hypertension
   Hypercholesterolemia
   Heart Disease
   Autonomic Dysreflexia
   Peripheral Vascular Disease
   Any HAI
*Statistically significant difference.
HA = high altitude, HAI = high altitude illness, MS = multiple sclerosis, NA = not applicable, SD = standard deviation, TBI = traumatic brain injury.
Table 4.
Acute mountain sickness (AMS) statistics for each group.
*Statistically significant difference.
LLS = Lake Louise Score, SD = standard deviation.Variable
Active 
Controls
(n = 19)
Inactive 
Controls
(n = 39)
TBI
(n = 29)
Paraplegia
(n = 38)
Tetraplegia
(n = 28)
MS
(n = 15)
p-Value
Average LLS, Mean ± SD 1.2 ± 1.1 1.7 ± 1.7 2.4 ± 2.0 2.6 ± 1.9 2.2 ± 2.1 2.0 ± 1.8 0.06
Cases Diagnosed, No. (%) 8 (42.1) 14 (35.9) 13 (44.8) 21 (55.3) 10 (35.7) 6 (40.0) 0.58
Duration of AMS Symptoms, No. of d (Range) 1 (1–2) 1 (1–3) 2 (1–3) 1 (1–3) 1 (1–3) 1.5 (1–3) 0.56
Severity, No. (%) 1 (5.3) 3 (7.7) 6 (20.7) 8 (21.1) 4 (14.3) 2 (13.3) 0.41
Days Subjects at Clinic when Completed First 
LLS, Median (Range)
1 (0–3) 2 (0–4) 1 (1–4) 1 (0–3) 1 (1–3) 1 (0–4) 0.09
Symptom
Subgroup*
Active Controls
(n = 19)
Inactive Controls
(n = 39)
TBI
(n = 29)
Paraplegia
(n = 38)
Tetraplegia
(n = 28)
MS
(n = 15)
Headache 10 (52.6) 19 (48.7) 17 (58.6) 27 (71.1) 14 (50.0) 8 (53.3)
Gastrointestinal 2 (10.5) 9 (23.1) 8 (27.6) 14 (36.8) 5 (17.9) 6 (40.0)
Fatigue 11 (57.9) 21 (53.8) 19 (65.5) 23 (60.5) 17 (60.7) 10 (66.7)
Dizziness 3 (15.8) 12 (30.8) 11 (27.9) 15 (39.5) 11 (39.3) 3 (20.0)
Difficulty Sleeping 7 (36.8) 22 (56.4) 15 (51.7) 27 (71.1) 14 (50.0) 7 (46.7)
Variable 2007 2008 2009 Total
Visits in Medical Area
Total No. of All Visits to Medical Area (Athletes, Volunteers, Trainers) 182 194 172 366
Total No. of Unique People Treated in Medical Area 161 153 135 449
Total No. of Unique People Diagnosed with AMS in Medical Area 7 6 9 22
Athletes in Medical Area
Total No. of All Athlete Visits (Athletes Only) 150 149 145 444
Total No. of Unique Athletes Treated in Medical Area 133 113 111 357
Total No. of Unique Athletes Diagnosed with AMS in Medical Area 7 5 7 19
Average Age of Athletes Treated for AMS 54 42 49 145
Disabilities of Athletes Diagnosed with AMS in Medical Area: Tally No. for Each Category
Traumatic Brain Injury — 2 2 4
Spinal Cord Injury 4 1 3 8
Stroke — — — —
Visual Impairment 1 — 1 2
Amputations — 1 1 2
Multiple Sclerosis — — — —
Other 2 1 3
Treatments Given: Tally No. for Each Category
Oxygen — 1 2 3
Hydration 3 2 2 7
Aspirin — — — —
Nonsteroidal Anti-Inflammatory Drugs 2 — 1 3
Acetaminophen 3 — 3 6
Return to Low Altitude — — — —
Acetazolamide 7 3 5 15
Dexamethasone — 1 1 2
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Table 5.
Acute mountain sickness (AMS) statistics for each subgroup, based on neurological impairments in athletes.
LLS = Lake Louise Score, MS = multiple sclerosis, SD = standard deviation, TBI = traumatic brain injury.
Table 6.
Subjects in each subgroup reporting acute mountain sickness symptoms in Lake Louise Score questionnaire. Data shown as No. (%).
*n in each subgroup represents 100%.
Table 7.
Number of athletes who visited the medical area, with their disabilities, and treatment modalities for acute mountain sickness (AMS).Average LLS Sex Age Category h/o AMS h/o Headache Average LLS
Correlation Coefficient 0.01 0.083 0.189 0.164 0.183 1
Significance (2-tailed) 0.878 0.133 0.003* 0.013* 0.006* —
Model
Coefficients
Unstandardized 
Coefficients
Standardized Coefficients Collinearity Statistics
B SE Beta t Sig. Tolerance VIF F Sig.
Durbin-
Watson
1 (Constant) 0.835 0.354 2.358 0.02 5.888 0.001a*
Category 0.186 0.056 0.25 3.295 0.001 0.986 1.014
h/o Headache 0.736 0.328 0.188 2.241 0.026 0.801 1.248
h/o AMS in Past 0.32 0.413 0.065 0.775 0.439 0.81 1.234
2 (Constant) 0.85 0.353 2.409 0.017 8.552 <0.001b* 1.98
Category 0.186 0.056 0.25 3.299 0.001 0.986 1.014
h/o Headache 0.846 0.295 0.217 2.863 0.005 0.986 1.014
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DISCUSSION
As  with  our  previous  study,  there  was  an  overall 
higher occurrence of AMS in the entire study population 
(42.85%),  and  within  specific  subgroups  as  compared 
with previously reported data (25.00%) within the same 
region [11,21]. Several factors may explain these find-
ings. First, the majority of the study population included 
individuals with neurological impairments and the possi-
ble implications of the various pathophysiological pro-
cess involved with these neurological impairments could 
affect  the  process  of  acclimatization,  precipitating  the 
symptoms of AMS. Second, the active and inactive con-
trols had a high number of volunteers and staff who could 
have  been  more  active  than  their  baseline  activity  at 
lower altitudes by participating in events that may have 
been more physically demanding than hiking, climbing, 
and trekking, which were the sports commonly reported 
in previous literature. In addition, all our subjects had a 
rapid  ascent  and  many  participated  in  high  intensity 
sporting events soon after arriving at HA.
Individuals with paraplegia trended toward having a 
higher occurrence of AMS (55.3%), higher LLS (2.6 ± 
1.9), and more severe symptoms (21.1%) than the other 
subgroups (Table 4), although the results were not statis-
tically significant. Our observation was that many of the 
athletes with paraplegia participated in some of the most 
physically demanding sports at the NVWSC as compared 
with those with tetraplegia and more heavily relied on 
upper-limb  muscle  groups  for  strength  and  endurance, 
which can increase aerobic exertion and may have made 
some  symptoms  more  prevalent,  which  thereby  could 
have caused an increase in their LLS. Also, the intrinsic 
fatigue of the muscles in patients with SCI [22] could 
have been aggravated by the physical exertion at HA, 
thereby causing an increase in the reporting of fatigue as 
a symptom and increasing average LLS.
Despite the 42 percent of the subjects in this study 
meeting diagnostic criteria, few sought medical treatment 
even after prompting. Most likely, many individuals may 
think the symptoms are self-limiting or may try to self-
treat. Most symptoms fell into the mild range and lasted 
on average 1 to 2 d. Since only 22 individuals were diag-
nosed with AMS, we could estimate that possibly <2 per-
cent of those with AMS symptoms sought treatment.
Table 8.
Pearson correlation coefficient for predictor variables.
*Statistically significant difference.
AMS = acute mountain sickness, h/o = history of, LLS = Lake Louise Score.
Table 9.
Regression model (backward analysis) to predict average Lake Louise Score (LLS).
aDependent variable: average LLS.
bh/o past AMS and headache.
*Statistically significant difference.  
AMS = acute mountain sickness, h/o = history of, SE = standard error, Sig. = significance, VIF = variance inflation factor.260
JRRD, Volume 50, Number 2, 2013
The significant findings from the regression analysis 
indicate that the three variables, the presence of a neuro-
logical impairment, prior history of occurrence of AMS, 
and prior occurrence of headache at HA correlate posi-
tively with the average LLS and could be used as predic-
tors for the average LLS. Thus, clinicians should consider 
obtaining this information from the patient’s history, par-
ticularly among individuals with neurological impairments 
traveling to HA. While there are no clear indications for 
prophylaxis, this information may help determine who will 
be more likely to have more symptoms.
LIMITATIONS
Although a large study population was recruited, the 
subjects  within  individual  subgroups  with  the  various 
disabilities were unevenly distributed, which could have 
contributed to the insignificant subgroup comparisons in 
the level II analysis. Also, because of the prescreening of 
participants before the NVWSC, the external validity of 
the study may have been limited to individuals without 
serious and unstable medical conditions.
While consumption of alcohol did not seem to con-
found the results, subjects may have underreported alco-
hol consumption. This study also did not account for the 
active medications the subjects were on, which may have 
multiple interactions with the cardiovascular and renal 
systems, both of which are actively involved in the pro-
cess of acclimatization.
Although the regression model could be generalized 
for the larger population, only three variables could be 
accounted for from this study because of the size of the 
study  population.  More  variables  should  be  studied  in 
future studies to evaluate for more accurate predictors for 
the LLS or for the occurrence of AMS itself.
CONCLUSIONS
While there were no differences among subject groups 
with respect to occurrence of AMS based on their disabil-
ity, this study shows that LLS in athletes with disabilities 
due  to  neurological  impairments  is  significantly  higher 
than in those without disabilities. The most common symp-
toms reported are fatigue and headache. The occurrence 
may be underestimated or possibly underreported clinically 
because many do not seek treatment. Hence, individuals, 
specifically  those  with  neurological  impairments,  should 
be carefully assessed with a detailed history to identify any 
predisposing factors, specifically prior history of AMS and 
prior occurrence of headache at high altitude.
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